Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Speakers' Biographies 4Th Annual Short Course in Medical Virology Of
Speakers’ Biographies 4th Annual Short Course in Medical Virology of the GVN Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS. As a member of the Population Sciences Program of the Cancer Center and a cancer epidemiologist, I conduct research on the epidemiology of cancer. At this time, I am the PI of the NIH funded African Collaborative Center for Microbiome and Genomics Research (ACCME) which is one of the NIH/Wellcome Trust funded Human Heredity and Health in Africa (H3Africa) initiative on genomics research and education in Africa. ACCME’s current project is enrolling 10,000 women in Nigeria and Zambia and following them up every 6 months for research focused on integrative epidemiology of persistent high risk HPV infection, host germline and somatic genomics and epigenomics, and vaginal microenvironment (cytokines and microbiome) and risk of cervical cancer. As part of this project, I established a comprehensive genomics laboratory in Nigeria including facilities for epigenetics and next generation sequencing using Illumina NextSeq500. The genomics lab is linked to an NIH funded biorepository at IHVN. I also direct the Fogarty funded West African Bioethics Training program which has provided medium term training leading to Certificates in Research Ethics for 842 biomedical researchers, Masters’ degree in Bioethics to 34 individuals and Online WAB-CITI Training program to 6115 participants in West Africa. In Baltimore, I am working with colleagues at the University of Maryland Greenebaum Cancer Center and University of Maryland College Park to develop a research program on cancer disparities among Africans in Africa, recent African immigrants to the United States and African Americans in order to better understand the role of genetics, environment cultural and socio- economic factors in cancer prevention, treatment seeking behavior and outcomes. -
Ebola Virus VP40 Real-Time RT-PCR Assay for Use Under an Emergency Use Authorization Only
Ebola Virus VP40 Real-Time RT-PCR Assay Centers for Disease Control and Prevention For Use Under an Emergency Use Authorization Only Instructions for Use January 2016 Page 0 of 50 Table of Contents Introduction .................................................................................................................................... 2 Specimens ....................................................................................................................................... 3 Equipment and Consumables ........................................................................................................ 3 Quality Control ............................................................................................................................... 5 Nucleic Acid Extraction ................................................................................................................. 7 Testing Algorithm .......................................................................................................................... 8 rRT-PCR Assay .............................................................................................................................. 9 Interpreting Test Results .............................................................................................................. 14 Overall Test Interpretation and Reporting Instructions ............................................................. 18 Assay Limitations, Warnings and Precautions .......................................................................... -
WHO Expert Committee on Biological Standardization: Sixty-Eighth Report (WHO Technical Report Series, No
This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the 1011 adoption of international recommendations for the production WHO Technical Report Series and control of vaccines and other biological substances, and the establishment of international biological reference materials. 1011 Following a brief introduction, the report summarizes a number WHO of general issues brought to the attention of the Committee. The next part of the report, of particular relevance to manufacturers Expert on Biological Standardization Committee and national regulatory authorities, outlines the discussions held on the development and adoption of new and revised WHO Recommendations, Guidelines and guidance documents. Following these discussions, WHO Guidelines on the quality, safety and efficacy of Ebola vaccines, and WHO Guidelines on procedures and data requirements for changes to approved biotherapeutic products were adopted on the recommendation of the Committee. In addition, the following two WHO guidance documents on the WHO prequalification of in vitro diagnostic medical devices were also adopted: (a) Technical Specifications Series (TSS) for WHO Prequalification – WHO Expert Committee Diagnostic Assessment: Human immunodeficiency virus (HIV) rapid diagnostic tests for professional use and/or self- on Biological testing; and (b) Technical Guidance Series (TGS) for WHO Prequalification – Diagnostic Assessment: Establishing stability of in vitro diagnostic medical devices. Standardization Subsequent -
Virus-Host Interaction: the Multifaceted Roles of Ifitms And
Virus-Host Interaction: The Multifaceted Roles of IFITMs and LY6E in HIV Infection DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jingyou Yu Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2018 Dissertation Committee: Shan-Lu Liu, MD, PhD, Advisor Patrick L. Green, PhD Jianrong Li, DVM., PhD Jesse J. Kwiek, PhD Copyrighted by Jingyou Yu 2018 Abstract With over 1.8 million newly infected people each year, the worldwide HIV-1 epidemic remains an imperative challenge for public health. Recent work has demonstrated that type I interferons (IFNs) efficiently suppress HIV infection through induction of hundreds of interferon stimulated genes (ISGs). These ISGs target distinct infection stages of invading pathogens and shape innate immunity. Among these, interferon induced transmembrane proteins (IFITMs) and lymphocyte antigen 6 complex, locus E (LY6E) have been shown to differentially modulate viral infections. However, their effects on HIV are not fully understood. In my thesis work, I provided evidence in Chapter 2 showing that IFITM proteins, particularly IFITM2 and IFITM3, specifically antagonize the HIV-1 envelope glycoprotein (Env), thereby inhibiting viral infection. IFITM proteins interacted with HIV-1 Env in viral producer cells, leading to impaired Env processing and virion incorporation. Notably, the level of IFITM incorporation into HIV-1 virions did not strictly correlate with the extent of inhibition. Prolonged passage of HIV-1 in IFITM-expressing T lymphocytes led to emergence of Env mutants that overcome IFITM restriction. The ability of IFITMs to inhibit cell-to-cell infection can be extended to HIV-1 primary isolates, HIV-2 and SIVs; however, the extent of inhibition appeared to be virus- strain dependent. -
A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures
viruses Communication A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures Ryan P. Bennett 1,† , Courtney L. Finch 2,† , Elena N. Postnikova 2 , Ryan A. Stewart 1, Yingyun Cai 2 , Shuiqing Yu 2 , Janie Liang 2, Julie Dyall 2 , Jason D. Salter 1 , Harold C. Smith 1,* and Jens H. Kuhn 2,* 1 OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA; [email protected] (R.P.B.); [email protected] (R.A.S.); [email protected] (J.D.S.) 2 NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA; courtney.fi[email protected] (C.L.F.); [email protected] (E.N.P.); [email protected] (Y.C.); [email protected] (S.Y.); [email protected] (J.L.); [email protected] (J.D.) * Correspondence: [email protected] (H.C.S.); [email protected] (J.H.K.); Tel.: +1-585-697-4351 (H.C.S.); +1-301-631-7245 (J.H.K.) † These authors contributed equally to this work. Abstract: Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody- based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane. -
Defining the Multiplicity and Type of Infection for the Production of Zaire Ebola Virus-Like Particles in the Insect Cell Baculovirus Expression System
DEFINING THE MULTIPLICITY AND TYPE OF INFECTION FOR THE PRODUCTION OF ZAIRE EBOLA VIRUS-LIKE PARTICLES IN THE INSECT CELL BACULOVIRUS EXPRESSION SYSTEM Ana Ruth Pastor, Instituto de Biotecnología, Universidad Nacional Autónoma de México Av. Universidad 2001 Col. Chamilpa, México [email protected] Gonzalo González-Domínguez, Instituto de Biotecnología. Universidad Nacional Autónoma de México Carlos F. Arias, Instituto de Biotecnología. Universidad Nacional Autónoma de México Alejandro Alagón, Instituto de Biotecnología. Universidad Nacional Autónoma de México Octavio T. Ramírez, Instituto de Biotecnología. Universidad Nacional Autónoma de México Laura A. Palomares, Instituto de Biotecnología. Universidad Nacional Autónoma de México Key Words: Ebola virus, ZEBOV-VLP’s, coinfection, hemorrhagic fever, immunogenic response. Ebola virus hemorrhagic fever affects thousands of people worldwide with high mortality rates. The Ebola virus has a short incubation time between 2-21 days and death usually occurs within 4-10 days1. Ebola virus disease is characterized by a sudden onset of fever, weakness, headache, diarrhea and vomiting, internal and external bleeding2. In the Filovirus family, Zaire Ebola virus (ZEBOV) is the most aggressive and virulent species, its fatality rates have been reported to be up to 90%3. Even when important advances in vaccine development have occurred, the need of safe and effective vaccines persists4. An alternative is the production of virus-like particles, which are formed by the recombinant virus structural proteins that self-assemble into highly immunogenic structures5. The ZEBOV contains three main structural proteins: the glycoprotein (GP), the viral matrix protein 40 (VP40) and the nucleoprotein (NP). GP induces humoral and cellular responses by itself but when VP40 is co-expressed, the immune response increases in a mouse model6. -
Defining the Multiplicity and Time of Infection for the Production of Zaire
Vaccine 37 (2019) 6962–6969 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Defining the multiplicity and time of infection for the production of Zaire Ebola virus-like particles in the insect cell-baculovirus expression system Ana Ruth Pastor a,1, Gonzalo González-Domínguez a,b,1, Marco A. Díaz-Salinas c, Octavio T. Ramírez a, ⇑ Laura A. Palomares a, a Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Ave. Universidad 2001, Cuernavaca, Morelos 62210, Mexico b Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico c Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Ave. Universidad 2001, Cuernavaca, Morelos 62210, Mexico article info abstract Article history: The Ebola virus disease is a public health challenge. To date, the only available treatments are medical Available online 28 June 2019 support or the emergency administration of experimental drugs. The absence of licensed vaccines against Ebola virus impedes the prevention of infection. Vaccines based on recombinant virus-like particles (VLP) Keywords: are a promising alternative. The Zaire Ebola virus serotype (ZEBOV) is the most aggressive with the high- Ebola virus disease est mortality rates. Production of ZEBOV-VLP has been accomplished in mammalian and insect cells by Virus-like particles the recombinant coexpression of three structural proteins, the glycoprotein (GP), the matrix structural ZEBOV-VLP protein VP40, and the nucleocapsid protein (NP). However, specific conditions to manipulate protein con- Design of experiments centrations and improve assembly into VLP have not been determined to date. -
This Is How You Get Ebola, As Explained by Science
This is how you get Ebola, as explained by science Written and illustrated by Ruth Tam August 21, 2014 at 10:24 AM EDT A colorized, magnified electron microscope image of the Ebola virus growing out of an infected VERO 46 cell. Image by National Institute of Allerfy and Infectious Diseases What is Ebola? Ebola is one of the world’s most virulent diseases. It comes from an extended family of viruses called Filoviridae, which also include the deadly Marburg virus. It is a swift and effective killer, known to kill up to 90 percent of those it infects. And it is a “hemorrhagic fever virus,” which means it causes fluid to leak from blood vessels, resulting in a dangerously low drop in blood pressure. Understanding Ebola requires an understanding of viruses and how they work. “Viruses,” science writer Carl Zimmer writes in his book “A Planet of Viruses”, “can replicate themselves, despite their paltry genetic instructions, by hijacking other forms of life. They… inject their genes and proteins into a host cell, which they [manipulate] into producing new copies of the virus. One virus might go into a cell, and within a day, a thousand viruses [come] out.” All viruses contain “attachment proteins,” which, as the name suggests, attach to host cells through the cells’ “receptor sites.” This is how they invade healthy human cells. While some virus particles are shaped like spheres, the particles that make up Ebola are filament-like in structure, giving them more surface area to potentially attack a greater number of cells. Each Ebola virus particle is covered in a membrane of these attachment proteins, or glycoproteins. -
Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using Mtor Inhibitors
viruses Article Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors Daniel O. Pinto 1 , Catherine DeMarino 1, Thy T. Vo 1, Maria Cowen 1, Yuriy Kim 1, Michelle L. Pleet 1, Robert A. Barclay 1, Nicole Noren Hooten 2 , Michele K. Evans 2, Alonso Heredia 3, Elena V. Batrakova 4, Sergey Iordanskiy 5 and Fatah Kashanchi 1,* 1 Laboratory of Molecular Virology, School of Systems Biology, George Mason University, Manassas, VA 20110, USA; [email protected] (D.O.P.); [email protected] (C.D.); [email protected] (T.T.V.); [email protected] (M.C.); [email protected] (Y.K.); [email protected] (M.L.P.); [email protected] (R.A.B.) 2 Laboratory of Epidemiology and Population Science, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; [email protected] (N.N.H.); [email protected] (M.K.E.) 3 Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201, USA; [email protected] 4 Department of Medicine, University of North Carolina HIV Cure Center; University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; [email protected] 5 Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA; [email protected] * Correspondence: [email protected]; Tel.: +703-993-9160; Fax: +703-993-7022 Received: 17 July 2020; Accepted: 10 August 2020; Published: 13 August 2020 Abstract: HIV-1 infects 39.5 million people worldwide, and cART is effective in preventing viral spread by reducing HIV-1 plasma viral loads to undetectable levels. -
Mrna Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation
REVIEWS mRNA vaccines for infectious diseases: principles, delivery and clinical translation Namit Chaudhary 1, Drew Weissman2 and Kathryn A. Whitehead 1,3 ✉ Abstract | Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism- inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts. Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research is required to optimize mRNA design, intracellular delivery and applications beyond SARS-CoV-2 prophylaxis. In this Review, we describe the technologies that underlie mRNA vaccines, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles. We also overview the pipeline of mRNA vaccines against various infectious disease pathogens and discuss key questions for the future application of this breakthrough vaccine platform. Vaccination is the most effective public health inter- and excessive immunostimulation. Fortunately, a few vention for preventing the spread of infectious dis- tenacious researchers and companies persisted. And eases. Successful vaccination campaigns eradicated over the past decade, by determining mRNA pharma- life- threatening diseases such as smallpox and nearly cology, developing effective delivery vehicles and con- eradicated polio1, and the World Health Organization trolling mRNA immunogenicity, interest in clinical estimates that vaccines -
Ebola and Marburg Virus Matrix Layers Are Locally Ordered Assemblies Of
RESEARCH ARTICLE Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers William Wan1,2†, Mairi Clarke1, Michael J Norris3, Larissa Kolesnikova4, Alexander Koehler4, Zachary A Bornholdt5‡, Stephan Becker4, Erica Ollmann Saphire3, John AG Briggs1,6* 1Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany; 2Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, Martinsried, Germany; 3Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, United States; 4Institut fu¨ r Virologie, Philipps-Universita¨ t Marburg, Hans-Meerwein-Straße, Marburg, Germany; 5The Scripps Research Institute, La Jolla, United States; 6Structural Studies Division, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom Abstract Filoviruses such as Ebola and Marburg virus bud from the host membrane as *For correspondence: enveloped virions. This process is achieved by the matrix protein VP40. When expressed alone, [email protected] VP40 induces budding of filamentous virus-like particles, suggesting that localization to the plasma membrane, oligomerization into a matrix layer, and generation of membrane curvature are intrinsic Present address: †Department properties of VP40. There has been no direct information on the structure of VP40 matrix layers of Biochemistry and Center for Structural Biology Vanderbilt within viruses or virus-like particles. We present structures of Ebola and Marburg VP40 matrix University, Nashville, United layers in intact virus-like particles, and within intact Marburg viruses. VP40 dimers assemble States; ‡Mapp extended chains via C-terminal domain interactions. These chains stack to form 2D matrix lattices Biopharmaceutical, Inc, San below the membrane surface. These lattices form a patchwork assembly across the membrane and Diego, United States suggesting that assembly may begin at multiple points. -
Vesicular Release of Ebola Virus Matrix Protein VP40
Virology 283, 1–6 (2001) doi:10.1006/viro.2001.0860, available online at http://www.idealibrary.com on View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector RAPID COMMUNICATION Vesicular Release of Ebola Virus Matrix Protein VP40 Joanna Timmins, Sandra Scianimanico, Guy Schoehn, and Winfried Weissenhorn1 EMBL, 6 rue Jules Horowitz, B.P. 181, 38042 Grenoble, France Received September 20, 2000; returned to author for revision October 26, 2000, accepted February 7, 2001 We have analysed the expression and cellular localisation of the matrix protein VP40 from Ebola virus. Full-length VP40 and an N-terminal truncated construct missing the first 31 residues [VP40(31–326)] both locate to the plasma membrane of 293T cells when expressed transiently, while a C-terminal truncation of residues 213 to 326 [VP40(31–212)] shows only expression in the cytoplasm, when analysed by indirect immunofluorescence and plasma membrane preparations. In addition, we find that full-length VP40 [VP40(1–326)] and VP40(31–326) are both released into the cell culture supernatant and float up in sucrose gradients. The efficiency of their release, however, is dependent on the presence of the N-terminal 31 residues. VP40 that is released into the supernatant is resistant to trypsin digestion, a finding that is consistent with the formation of viruslike particles detected by electron microscopy. Together, these results provide strong evidence that Ebola virus VP40 is sufficient for virus assembly and budding from the plasma membrane. © 2001 Academic Press INTRODUCTION to liposomes (12). Although it has been shown that the VSV matrix protein is released from cells in the form of Ebola virus and Marburg virus (Filoviridae) are non- lipid vesicles (13, 14), the efficiency of assembly and segmented negative-strand RNA viruses (Mononegavi- particle release depends on interactions with cellular rales) that cause severe hemorrhagic fever in humans proteins mediated by a conserved WW domain binding (1–3).